US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017

After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.

Biopharma In Perspective 2016-2017

Generalist investors that gambled on the US biopharmaceutical initial public offering market between 2013 and mid-2015 are largely gone, leaving health care specialists to bet on less risky drug developer IPOs in 2016 – a trend that’s expected to continue in 2017.

The biopharma IPO market may be reaching a sort of equilibrium as companies vetted by experienced health care investors and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Verona’s COPD Launch Success Sealed Merck Buyout Interest

 

SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.

Metabolic Disease-Focused Poxel Teeters On The Edge

 

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

More from Business

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer

 
• By 

The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.